Haemonetics Co. (NYSE:HAE) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its position in shares of Haemonetics Co. (NYSE:HAE) by 31.5% in the fourth quarter, HoldingsChannel reports. The firm owned 16,415 shares of the medical instruments supplier’s stock after selling 7,539 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Haemonetics were worth $1,282,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Skylands Capital LLC boosted its holdings in Haemonetics by 16.6% in the fourth quarter. Skylands Capital LLC now owns 27,175 shares of the medical instruments supplier’s stock valued at $2,122,000 after purchasing an additional 3,875 shares during the last quarter. Keene & Associates Inc. boosted its stake in shares of Haemonetics by 7.2% in the fourth quarter. Keene & Associates Inc. now owns 10,904 shares of the medical instruments supplier’s stock worth $851,000 after buying an additional 730 shares during the last quarter. Cardinal Capital Management boosted its stake in shares of Haemonetics by 5.4% in the fourth quarter. Cardinal Capital Management now owns 18,284 shares of the medical instruments supplier’s stock worth $1,428,000 after buying an additional 935 shares during the last quarter. Peregrine Capital Management LLC grew its holdings in Haemonetics by 1.7% during the fourth quarter. Peregrine Capital Management LLC now owns 141,803 shares of the medical instruments supplier’s stock worth $11,072,000 after acquiring an additional 2,400 shares during the period. Finally, Principal Financial Group Inc. raised its position in Haemonetics by 1.0% during the fourth quarter. Principal Financial Group Inc. now owns 156,734 shares of the medical instruments supplier’s stock valued at $12,238,000 after acquiring an additional 1,475 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 1.4 %

Shares of HAE opened at $65.50 on Friday. Haemonetics Co. has a 12-month low of $58.80 and a 12-month high of $97.97. The firm has a market capitalization of $3.29 billion, a P/E ratio of 25.79, a P/E/G ratio of 1.11 and a beta of 0.39. The firm has a 50-day moving average price of $70.86 and a 200 day moving average price of $76.00. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Sell-side analysts forecast that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on HAE. Raymond James restated a “strong-buy” rating and issued a $115.00 price objective (down previously from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities cut their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.